Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5905307 | 1.00 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL5905617 | 1.00 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14642003 | 0.89 | MAPT (0.54) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3017418 | 0.89 | MAPT (0.54) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3017415 | 0.89 | MAPT (0.54) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL13209102 | 0.89 | MAPT (0.54) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL16033453 | 0.87 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL16033454 | 0.87 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL16070070 | 0.87 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3828022 | 0.86 | FPR1 (0.54) | SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054484-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2022-05-19 | — | — | US | disclosed |
| EP-3297438-B1 | CCR2 MODULATORS | CHEMOCENTRYX INC (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3297438-B1 | CCR2 MODULATORS | CHEMOCENTRYX INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| EP-3297438-A1 | CCR2 MODULATORS | ChemoCentryx, Inc. (US) | 2018-03-28 | — | — | EP | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| WO-2016187393-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016187393-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CCR2, CCR1, CCR5 | SLC6A3 2168/4885SLC6A4 2407/4885SLC6A2 2961/4885 |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | SLC6A3 2168/4885SLC6A4 2407/4885SLC6A2 2961/4885 |
| US-12054484-B2 | Substituted tetrahydropyrans as CCR2 modulators | CCR2, CCR1, CCR5 | SLC6A3 3045/4885SLC6A4 3221/4885SLC6A2 3777/4885 |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | SLC6A3 2168/4885SLC6A4 2407/4885SLC6A2 2961/4885 |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | SLC6A3 3154/4885SLC6A4 3373/4885SLC6A2 3888/4885 |
| US-20160340356-A1 | CCR2 MODULATORS | CCR2, CCR1, CCR5 | SLC6A3 3699/4885SLC6A4 4017/4885SLC6A2 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.